Opalite Health
AI speech-to-speech interpreter for doctor-patient conversations in real time.
On the record
Checkpoint: Confirmation of the promised large healthcare enterprise rollout, originally stated for around March 2026
The call
Opalite has a real regulatory tailwind and a working demo, but its promised enterprise deal and error-rate claims remain unverified while bigger interpretation firms already ship AI-plus-human products.
Opalite Health builds software that uses artificial intelligence to help doctors and patients who speak different languages understand each other during medical visits. The company is not the only one doing this: better-funded rivals like Boostlingo and No Barrier AI already have working products, and giant tech companies like OpenAI and Google are building similar tools into their own AI systems that could do the same job cheaper or faster. The key question is whether Opalite can prove it can actually land large hospital clients and lock them in, the company claimed it would sign a big healthcare enterprise by January 2026, but that deal has not been publicly confirmed, which raises doubts about whether hospitals will actually buy from them or stick with cheaper AI alternatives.
Why
01
AI pressure: OpenAI GPT-4o voice, Google Gemini Live. Frontier voice models could add HIPAA-covered clinical translation directly, erasing the need for a standalone interpretation layer. Could AI do the core job? Only partly.
02
Bigger players: LanguageLine Solutions, CyraCom International, AMN Healthcare Language Services. These incumbents already run hybrid AI-plus-human interpretation at hospital scale, the exact niche Opalite is trying to enter. Could a giant copy it? Probably.
03
What protects it. A hybrid AI-plus-human workflow built for Section 1557 compliance, but the same design is used by every serious rival too.
What would change this call
Whether the large healthcare enterprise rollout claimed for March 2026 is confirmed with a named customer by Q3 2026. Shows if Opalite can convert pilots into referenceable enterprise deployments.
Publication of independent peer-reviewed validation of the 90%+ fewer errors claim. Tests whether Opalite's core accuracy claim holds up outside vendor-run studies.
Announcement of a Series A raise within 12 months of the Seed round. Indicates investor confidence in traction beyond seed-stage claims.
Publication of independent peer-reviewed validation of the 90%+ fewer errors claim. Tests whether Opalite's core accuracy claim holds up outside vendor-run studies.
Announcement of a Series A raise within 12 months of the Seed round. Indicates investor confidence in traction beyond seed-stage claims.
Key numbers
- Claims daily use across 10+ states
- Claims 90%+ fewer errors vs certified interpreters
- Team of about 3 people per YC jobs page
Named risks
- Core error-rate and cost-savings claims are vendor-authored, not independently peer-reviewed.
- Stated large healthcare enterprise rollout from January 2026 remains unconfirmed as of mid-2026.
- Hybrid AI+human moat is category-wide, shared by Boostlingo, GLOBO KAI, No Barrier AI, not proprietary.
- Hospital enterprise procurement cycles of 12-18 months could stall growth for a 3-person team.
- Regulatory tightening or loosening of Section 1557 human-in-loop rules could reshape addressable market.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Boostlingo | losing to | Claims 17,000+ interpreters and 3,000+ customers with own hybrid AI product as of March 11, 2026 |
| GLOBO KAI | losing to | Already shipping competing hybrid AI interpretation product per May 9, 2026 industry roundup |
| No Barrier AI | contesting | HIPAA-compliant AI medical interpreter founded by 20+ year speech AI veteran, competing directly, May 2026 |
| LanguageLine Solutions | contesting | Legacy human-interpreter network incumbent dominating OPI/VRI market that Opalite targets for disruption |
| Frontier model providers (OpenAI, Google Gemini) | losing to | General-purpose real-time speech translation improving, though clinical safety gaps persist per July 2026 research |
Questions people ask
- Is Opalite Health profitable?
- No revenue or ARR figures are publicly disclosed as of July 25, 2026. Opalite Health is a YC W26 seed-stage startup with roughly $500K to $645K total raised and a team of about 3 people, per CB Insights.
- Could AI replace Opalite Health's own product?
- Opalite's product IS an AI replacement play for human medical interpreters. Its moat is a human-escalation layer required by Section 1557 regulation, not proprietary tech; frontier models like GPT-4o voice could commoditize the core capability over time.
- Who are Opalite Health's biggest competitors?
- Incumbents LanguageLine Solutions, CyraCom International, and AMN Healthcare Language Services dominate today. AI-native rivals Boostlingo (17,000+ interpreters, 3,000+ customers claimed, per its own March 2026 blog), GLOBO KAI, and No Barrier AI already ship comparable hybrid AI products.
- Who owns Opalite Health?
- Opalite Health is privately held and pre-Series A, co-founded by CEO Cathleen Kuo, MD, and CTO Alex Mehregan, an ex-Apple Siri engineer. Seed investors include Y Combinator, Right Side Capital Management, Rebel Fund, Robinhood Ventures, and 007 Venture Partners, per Caplight, dated January 21, 2026.
- How much funding has Opalite Health raised?
- Reported totals vary: CB Insights lists $570K as of May 29, 2026, Caplight lists a $500K seed dated January 21, 2026, and Startup Geek lists $645K. No valuation has been publicly disclosed.
- Does Opalite Health have proof its AI is safer than human interpreters?
- Opalite claims '90%+ fewer errors' versus certified human interpreters based on a vendor-described blinded evaluation, dated July 4, 2026, but this has not been independently peer-reviewed. A separate Nature study published May 11, 2026 found competing AI translation apps unsuitable for safe clinical use.
Timeline
- 2026-07-04Startuphub.ai covers Opalite's 'Guardian' hybrid AI/human architecture and claimed error-rate stats
- 2026-05-31CompleteAITraining reports Opalite targeting 25 million limited-English-proficiency Americans
- 2026-05-29CB Insights snapshot lists $570K total raised, no disclosed revenue
- 2026-05-11Nature publishes prospective validation study finding AI translation apps unsafe for two-way clinical use
- 2026-05-07Coyote Ventures blog outlines Opalite's roadmap toward broader 'voice intelligence layer' for healthcare
- 2026-03-31Tryfondo covers Opalite Health's public launch
- 2026-01-21Opalite launches via Y Combinator's Launch YC program, claims use across 10+ states
- 2026-01-21Opalite states plan to roll out in a large healthcare enterprise within two months (unconfirmed)
- 2026-01-20Caplight records $500K seed round with named investors including YC and Rebel Fund
- 2025Opalite Health founded, later rebranded from earlier app name 'Calliope'
Revision history
27 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- Products, Competitors, Financials, Employees, Headquarters Locations (2026-05-29)
- Opalite Health: Helping Healthcare Providers Speak Any Language
- Opalite Health Funding
- Valuation, Funding Rounds & Stock Price (2026-01-20)
- Launch YC: Opalite Health (2026-01-21)
- Opalite · Real-time AI medical interpretation
- Claude's Corner: Opalite Health (2026-07-04)
- Jobs at Opalite Health
- Opalite Health, Coyote Ventures (2026-05-07)
- Opalite (Formerly Calliope) App
- Top Language Interpretation Services in Healthcare and the Next Infrastructure Layer (2026-05-09)
- 4 Artificial Intelligence (AI) Interpreting Providers (2026-03-11)